Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent cancer and infectious diseases, announces today that it has appointed Mariem Charafeddine as its new chief medical officer.

Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products. She has also previously worked in international medical leadership roles and drug development in infectious diseases.

"We are delighted to have Mariem join our team as we advance towards the Phase IIb read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO.

He continued, “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”